NCT06077864
SYNCHRONIZE-1 — survodutide in obesity
Phase Phase 3
Status Recruiting
Indication Obesity
Enrollment 2,600
Last updated:Jul 15, 2026Source:ClinicalTrials.govVerified:NCT ID verified against public registryData provider:ClinicalTrials.gov API v2
Overview
- NCT ID
- NCT06077864
- Phase
- Phase 3
- Status
- Recruiting
- Indication
- Obesity
- Primary completion
- 6/1/2027
- Enrollment (planned/actual)
- 2,600
- Sponsor
- Zealand Pharma
- Peptide
- Survodutide
Peptide under study
Survodutide
GLP-1 / glucagon dual agonist · Phase 3